RT Journal Article
SR Electronic
T1 Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.16.21264948
DO 10.1101/2021.10.16.21264948
A1 Havervall, Sebastian
A1 Marking, Ulrika
A1 Greilert-Norin, Nina
A1 Gordon, Max
A1 Ng, Henry
A1 Christ, Wanda
A1 Blom, Kim
A1 Phillipson, Mia
A1 Nilsson, Peter
A1 Hober, Sophia
A1 Klingström, Jonas
A1 Mangsbo, Sara
A1 Åberg, Mikael
A1 Thålin, Charlotte
YR 2021
UL http://medrxiv.org/content/early/2021/10/19/2021.10.16.21264948.abstract
AB Background Recent serological investigations imply waning immune responses following SARS-CoV-2 vaccination, but prior infection may impact the breadth and duration of vaccine immune responses.Methods Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU/ml) and neutralizing antibody titers against ten SARS-CoV-2 variants over seven months following BNT162b2 in healthcare workers with (n=111) and without (n=298) confirmed prior SARS-CoV-2 infection. A smaller group with (n=47) and without (n=61) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for three months.Results Vaccination (BNT162b2 and ChAdOx1 nCoV-19) following SARS-CoV-2 infection resulted in higher wild-type BAU/ml geometric mean titers (GMTs) at all sampling time points when compared to SARS-CoV-2 naïve vaccinees (all p<0.001). GMTs were 1875 BAU/ml in convalescent and 981 BAU/ml in naïve BNT162b2 vaccinees 6 weeks post vaccination. 29 weeks post vaccination, GMTs had decreased to 524 BAU/ml in convalescent and 148 BAU/ml in naïve vaccinees. GMT differences between convalescents and naïve following ChAdOx1 nCoV-19 mirrored those after BNT162b2, but the titers were 4.5-fold lower following ChAdOx1 ncov-19 as compared to those after BNT162b2 (p<0.001). Finally, at all time points, neutralizing antibody titers against all ten tested SARS-CoV-2 variants were at least 2 respectively 3-fold higher in SARS-CoV-2 recovered as compared to naïve vaccinees following BNT162b2 and ChAdOx1 nCoV-19, respectively (all p<0.001).Conclusions These findings of substantially more robust serological responses to vaccine after natural infection imply that prior infection may be taken into consideration when planning booster doses and design of current and future SARS-CoV-2 vaccine programs.Competing Interest StatementSoH has participated on AstraZeneca COVID-19 SCG Virtual Advisory Board. Otherwise, the authors declare no competing interests.Funding StatementThis work was funded by Jonas & Christina af Jochnick foundation; Lundblad family foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for Life Laboratory (SciLifeLab); Erling-Persson family foundation; CIMED and the Swedish Research Council. The funders above had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the Swedish Ethical Review Authority (dnr 2020-01653) and written informed consent was obtained from all study participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.